格隆汇勾股大数据显示，腾讯控股(00700)、小米集团-W(01810)、三花智控(02050)、中远海控(01919)、 金山软件(03888)、快手-W(01024)、巨子生物(02367)、碧桂园服务(06098)、名创优品(09896)、四环医 药(00460)、明源云(00909)、津上机床中国(01651)、多点数智(02586)、科济药业-B(02171)、富智康集团 (02038)、趣致集团(00917)、汇通达网络(09878)、海吉亚医疗(06078)、心玮医疗-B(06609)、德康农牧 (02419)、绿城服务(02869)、捷利交易宝(08017)、歌礼制药-B(01672)、VITASOY INT'L(00345)、同道猎 聘(06100)、海尔智家(06690)、荃信生物-B(02509)、知行科技(01274)、连连数字(02598)、昊海生物科技 (06826)、锅圈(02517)、叮当健康(09886)、天伦燃气(01600)、中远海发(02866)、信利国际(00732)、绿茶 集团(06831)、思派健康(00314)、希玛医疗(03309)、枫叶教育(01317)、北 ...

证券时报·数据宝统计，巨子生物在港交所公告显示，12月29日以每股34.280港元至34.760港元的价格回 购40.00万股，回购金额达1381.44万港元。该股当日收盘价34.560港元，下跌3.03%，全天成交额4.01亿 港元。 今年以来该股累计进行12次回购，合计回购480.00万股，累计回购金额1.69亿港元。（数据宝） 巨子生物回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.29 | 40.00 | 34.760 | 34.280 | 1381.44 | | 2025.12.23 | 40.00 | 36.480 | 35.740 | 1439.66 | | 2025.12.22 | 40.00 | 36.340 | 35.860 | 1442.97 | | 2025.12.19 | 40.00 | 35.520 | 34.540 | 1405.36 | | 2025.12.18 | 40.00 | 35.040 | 34.420 | 1388 ...

Core Viewpoint - The strategic partnership between Giant Bio and Nordberg Medical aims to leverage Giant Bio's patented recombinant collagen technology for global market expansion in the medical aesthetics sector, indicating a shift towards international growth opportunities [2][5][10]. Financial Performance - In the first half of the year, Giant Bio reported revenue of 31.13 billion yuan, a year-on-year increase of 22.52%, and a net profit attributable to shareholders of 11.82 billion yuan, up 20.23% [7]. - Despite positive growth, the revenue and net profit growth rates have slowed compared to previous years, where growth rates exceeded 40% [7]. - The company's gross margin for the first half of the year was 81.68%, down from previous years' figures of 85.11%, 84.14%, and 82.4% [7]. Strategic Developments - The partnership with Nordberg Medical allows Giant Bio to utilize the latter's established global marketing and sales network, facilitating quicker entry into international markets [5][10]. - Giant Bio received a medical device registration certificate for its recombinant type I α1 collagen product, marking a significant step into the professional medical sector [10][12]. Market Position and Competition - The competitive landscape in the recombinant collagen market is intensifying, with companies like Huaxi Bio and Jinbo Bio also making significant advancements [10][11]. - Jinbo Bio has established a lead in the market with multiple approved medical device registrations, highlighting Giant Bio's relatively slower progress in this area [11][12]. Stock Performance and Market Sentiment - Giant Bio's stock has seen a significant decline, dropping approximately 60% from its peak of 85.14 HKD per share earlier in the year, now trading at 34.56 HKD [12]. - The company announced a share buyback plan to repurchase up to 10% of its issued shares, reflecting confidence in its long-term strategy and growth potential [12].

智通财经APP讯，巨子生物(02367)发布公告，于2025年12月29日该公司斥资1381.44万港元回购40万 股，回购价格为每股34.28-34.76港元。 ...

巨子生物(02367)发布公告，于2025年12月29日该公司斥资1381.44万港元回购40万股，回购价格为每股 34.28-34.76港元。 ...

格隆汇12月29日丨巨子生物(02367.HK)公告，12月29日耗资1381.4万港元回购40万股，每股回购价 34.28-34.76港元。 ...

呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年12月23日 | 1 ...

Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), COSCO Shipping Holdings (01919), and Heng Rui Medicine (01276), with short ratios of 18.48%, 16.79%, and 15.54% respectively [1][2] - The companies with the largest absolute increase in short positions are CATL (03750), Lens Technology (06613), and UBTECH Robotics (09880), which increased by 2.35%, 2.34%, and 1.29% respectively [1][2] - The companies with the largest absolute decrease in short positions are Changfei Optical Fiber (06869), Mao Ge Ping (01318), and Meilan Airport (00357), which decreased by -1.26%, -0.68%, and -0.67% respectively [1][2] Group 2 - The latest short ratio for Vanke Enterprises (02202) is 18.48%, down from 19.04% previously [3] - The latest short ratio for COSCO Shipping Holdings (01919) is 16.79%, down from 16.79% previously [2] - The latest short ratio for Heng Rui Medicine (01276) is 15.54%, up from 3919.30 million shares to 4011.67 million shares [2]

12月26日，以"新开局、新动能、新征程"为主题的"启航·2025金融峰会"在北京圆满举办，大会由金融界主办，汇聚监管部门、行业协会、金融机构、上市 公司、媒体等数百位相关领导和重磅嘉宾。会上，第十四届金融界"金智奖"年度评选结果重磅揭晓，巨子生物荣获"杰出成长性企业"。 "金智奖"旨在树立高质量发展标杆，引导上市公司聚焦主业、持续创新、践行社会责任，推动资本向优质企业集聚。本届评选中，金融界上市公司研究院紧 密契合"十五五"规划建议中"提升上市公司质量"的要求，将高质量发展内核分解为社会责任、实业贡献、投资回报、成长前景、创新效率、杰出品牌六大维 度，以企业财务数据和公开信息为基础建立量化分析模型，最终覆盖A股、港股及中概股超8000家企业，评选出近200家获奖企业。 "杰出成长性企业"奖项的核心标准在于综合考察企业的持续增长潜力与高质量发展能力，重点考量企业在主业深耕、创新驱动、市场拓展、运营效率等关键 维度的综合表现。该奖项的设立，旨在挖掘具备长期发展韧性的优质企业，引导企业坚守创新初心、夯实成长根基，为实体经济高质量发展注入新活力，是 反映行业成长趋势、彰显企业发展潜力的重要标杆。 作为专业皮肤护理领 ...

Core Viewpoint - The article discusses the strategic partnership between Juzi Bio and Nordberg Medical, focusing on the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields, amidst challenges in the domestic consumption market [1][2]. Financial Performance - In the first half of 2025, Juzi Bio achieved revenue of 3.113 billion yuan, a year-on-year increase of 22.5%, with net profit exceeding 1.182 billion yuan, also showing over 20% growth [4]. - Despite overall growth, key financial indicators reveal challenges, such as a 27.5% increase in sales costs to 570 million yuan, which outpaced revenue growth, leading to pressure on gross margins [5]. - Research and development expenses decreased by 15.5% to 41.2 million yuan, attributed to some projects entering the results transformation phase [5]. Market Challenges - The main brand "Kefumei" reported revenue of 2.54 billion yuan, growing 22.7%, but faces challenges from industry slowdowns and intensified competition [5]. - Reports indicate a double-digit decline in sales during the Double Eleven shopping festival, with significant reductions in GMV on platforms like Douyin [5]. Strategic Shift - Juzi Bio is transitioning from a focus on scale expansion to a strategy emphasizing profit stability and structural adjustment due to market pressures [5]. - The recent approval of a Class III medical device registration certificate for recombinant collagen products marks a significant shift from consumer skincare to professional medical applications, enhancing the company's market position [7]. International Collaboration - The partnership with Nordberg Medical allows Juzi Bio to leverage established global networks, facilitating entry into the projected $10 billion market for injection-based medical aesthetics by 2026 [2]. - This collaboration represents a strategic "borrowing a boat to go to sea" approach, enabling Juzi Bio to access existing commercial channels without starting from scratch [8]. Product Development and Market Strategy - Juzi Bio's focus on professional medical products is expected to reshape its marketing strategies, moving from consumer-driven sales to professional education and B2B promotion [9]. - The company aims to build a dual engine of "consumer brand" and "professional technology" by reallocating resources towards products with global registration potential and strengthening international business teams [9].